Lexicon reported Q4 FY2025 total revenues of USD 5.5 million (USD 4.3 million licensing revenue and USD 1.1 million net product revenue from INPEFA). Q4 R&D expenses were USD 11.3 million (-57.6%) and SG&A expenses were USD 8.8 million (-72.8%). Q4 net loss was USD 15.5 million, or USD 0.04 per share. For FY2025, total revenues were USD 49.8 million (including USD 45.0 million licensing revenue and USD 4.6 million net product revenue), R&D expenses were USD 61.1 million (-27.7%), SG&A expenses were USD 37.3 million (-73.9%), and net loss was USD 50.3 million (USD 0.14 per share). Cash, investments and restricted cash totaled USD 125.2 million as of Dec. 31, 2025. On the business side, Lexicon said enrollment in the pivotal SONATA-HCM Phase 3 trial of sotagliflozin has surpassed 50%, with enrollment completion expected in mid-2026 and topline results in Q1 2027. The company said it remains on track for a potential 2026 NDA resubmission for sotagliflozin in type 1 diabetes, contingent on meeting FDA-identified exposure and safety data requirements via the STENO1 study. Lexicon also reported a positive FDA End-of-Phase 2 meeting for pilavapadin (LX9211) in diabetic peripheral neuropathic pain, with no objections to advancing into Phase 3. In February 2026, the company received USD 96.7 million in net proceeds from stock sales and a USD 10.0 million milestone payment from Novo Nordisk related to LX9851.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050659PRIMZONEFULLFEED9666137) on March 05, 2026, and is solely responsible for the information contained therein.
Comments